-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on RxSight, Lowers Price Target to $7

Benzinga·11/04/2026 10:14:03
Listen to the news
Needham analyst David Saxon maintains RxSight (NASDAQ:RXST) with a Buy and lowers the price target from $11 to $7.